New drug cocktail aims to outperform standard immunotherapy in bile duct cancer

NCT ID NCT07710885

Recruiting now Disease control Sponsor: Taiho Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This phase 3 trial tests whether a combination of two experimental drugs (futibatinib and zimberelimab) plus standard chemotherapy can help people with advanced biliary tract cancer live longer compared to current standard immunotherapy combinations. The study enrolls about 784 adults whose cancer has not been treated before and has spread or cannot be removed by surgery. Participants receive either the new drug combo or one of two approved immunotherapy regimens, all alongside chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of futibatinib, zimberelimab, gemcitabine, and cisplatin
What this could lead to: If successful, this combination could offer a new, more effective first-line treatment option for people with advanced biliary tract cancer, potentially extending survival.
What could go wrong: This is an early-stage comparison against existing treatments, and the new combination may not prove superior. Side effects from combining multiple drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates